Cynosure Group LLC purchased a new stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 4,429 shares of the company's stock, valued at approximately $1,831,000.
Other large investors have also recently made changes to their positions in the company. FMR LLC increased its stake in IDEXX Laboratories by 3.6% during the third quarter. FMR LLC now owns 290,861 shares of the company's stock worth $146,949,000 after purchasing an additional 10,017 shares during the period. D.A. Davidson & CO. grew its holdings in shares of IDEXX Laboratories by 9.5% in the third quarter. D.A. Davidson & CO. now owns 1,629 shares of the company's stock valued at $823,000 after purchasing an additional 142 shares in the last quarter. Quantbot Technologies LP purchased a new stake in IDEXX Laboratories during the 3rd quarter worth approximately $341,000. Glenmede Trust Co. NA lifted its holdings in IDEXX Laboratories by 2.6% during the 3rd quarter. Glenmede Trust Co. NA now owns 1,874 shares of the company's stock worth $947,000 after buying an additional 48 shares in the last quarter. Finally, Public Sector Pension Investment Board boosted its position in IDEXX Laboratories by 16.2% in the 3rd quarter. Public Sector Pension Investment Board now owns 3,578 shares of the company's stock valued at $1,808,000 after buying an additional 500 shares during the period. 87.84% of the stock is currently owned by institutional investors and hedge funds.
IDEXX Laboratories Stock Performance
NASDAQ IDXX traded down $17.03 during trading hours on Friday, hitting $393.73. 1,635,645 shares of the stock were exchanged, compared to its average volume of 592,305. IDEXX Laboratories, Inc. has a 12-month low of $390.11 and a 12-month high of $548.88. The stock has a 50-day moving average of $435.55 and a 200 day moving average of $440.31. The company has a market cap of $31.91 billion, a price-to-earnings ratio of 36.90, a price-to-earnings-growth ratio of 3.41 and a beta of 1.39. The company has a quick ratio of 0.95, a current ratio of 1.31 and a debt-to-equity ratio of 0.28.
Insider Transactions at IDEXX Laboratories
In related news, EVP George Fennell sold 9,986 shares of the company's stock in a transaction on Monday, February 10th. The stock was sold at an average price of $462.53, for a total transaction of $4,618,824.58. Following the transaction, the executive vice president now owns 8,176 shares of the company's stock, valued at $3,781,645.28. This represents a 54.98 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director M Anne Szostak sold 3,000 shares of the stock in a transaction on Friday, February 7th. The stock was sold at an average price of $465.94, for a total value of $1,397,820.00. Following the completion of the transaction, the director now owns 3,061 shares of the company's stock, valued at $1,426,242.34. The trade was a 49.50 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 2.11% of the company's stock.
Wall Street Analyst Weigh In
Several research analysts recently commented on the company. StockNews.com cut IDEXX Laboratories from a "buy" rating to a "hold" rating in a research note on Tuesday, March 25th. Bank of America upped their target price on shares of IDEXX Laboratories from $475.00 to $535.00 and gave the stock a "neutral" rating in a research note on Tuesday, February 4th. Barclays raised their price objective on shares of IDEXX Laboratories from $481.00 to $520.00 and gave the company an "overweight" rating in a report on Tuesday, February 4th. Piper Sandler boosted their target price on shares of IDEXX Laboratories from $435.00 to $510.00 and gave the stock a "neutral" rating in a research note on Monday, February 10th. Finally, Morgan Stanley decreased their price target on IDEXX Laboratories from $559.00 to $550.00 and set an "overweight" rating for the company in a report on Wednesday, January 29th. Four research analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, IDEXX Laboratories currently has an average rating of "Moderate Buy" and a consensus target price of $533.75.
Get Our Latest Report on IDXX
IDEXX Laboratories Profile
(
Free Report)
IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.
Further Reading
Before you consider IDEXX Laboratories, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IDEXX Laboratories wasn't on the list.
While IDEXX Laboratories currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
